Rivaroxaban Patent Expiration
Rivaroxaban is Used for reducing the risk of clot-related complications in various cardiovascular conditions, including deep vein thrombosis and pulmonary embolism in pediatric and adult patients. It was first introduced by Janssen Pharmaceuticals Inc
Rivaroxaban Patents
Given below is the list of patents protecting Rivaroxaban, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xarelto |
US10828310 (Pediatric) | Reducing the risk of cardiovascular events | Jul 31, 2039 | Janssen Pharms |
| Xarelto | US10828310 | Reducing the risk of cardiovascular events | Jan 31, 2039 | Janssen Pharms |
| Xarelto |
US9539218 (Pediatric) | Prevention and treatment of thromboembolic disorders | Aug 17, 2034 | Janssen Pharms |
| Xarelto | US9539218 | Prevention and treatment of thromboembolic disorders | Feb 17, 2034 | Janssen Pharms |
| Xarelto |
US9415053 (Pediatric) | Solid, orally administrable pharmaceutical composition |
May 13, 2025
(Expired) | Janssen Pharms |
| Xarelto |
US7157456 (Pediatric) | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb 28, 2025
(Expired) | Janssen Pharms |
| Xarelto | US9415053 | Solid, orally administrable pharmaceutical composition |
Nov 13, 2024
(Expired) | Janssen Pharms |
| Xarelto | US7157456 | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug 28, 2024
(Expired) | Janssen Pharms |
| Xarelto | US7585860 | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec 11, 2020
(Expired) | Janssen Pharms |
| Xarelto | US7585860 | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec 11, 2020
(Expired) | Janssen Pharms |
| Xarelto | US7592339 | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec 11, 2020
(Expired) | Janssen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rivaroxaban's patents.
Latest Legal Activities on Rivaroxaban's Patents
Given below is the list recent legal activities going on the following patents of Rivaroxaban.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Jun, 2024 | US9539218 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Apr, 2024 | US10828310 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jan, 2024 | US9415053 |
| Termination or Final Written Decision | 28 Jul, 2023 | US10828310 |
| Request for Trial Granted Critical | 19 Oct, 2022 | US10828310 |
| Petition Requesting Trial | 30 Sep, 2022 | US10828310 |
| Petition Requesting Trial | 27 Sep, 2022 | US10828310 |
| Petition Requesting Trial | 09 Sep, 2022 | US10828310 |
| Petition Requesting Trial | 08 Sep, 2022 | US10828310 |
| Request for Trial Granted Critical | 09 Aug, 2022 | US10828310 |
Rivaroxaban's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Rivaroxaban:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Rivaroxaban has 1 clinical trial that has been verified in 2024.
Rivaroxaban Generic API Manufacturers
Several generic applications have been filed for Rivaroxaban. The first generic version for Rivaroxaban was by Taro Pharmaceutical Industries Ltd and was approved on Mar 3, 2025. And the latest generic version is by Aurobindo Pharma Ltd and was approved on May 15, 2025.
Given below is the list of companies who have filed for Rivaroxaban generic, along with the locations of their manufacturing plants worldwide.
1. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 4 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
2. APOTEX
Apotex Inc has filed for 1 generic for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet | Prescription | ORAL | AB | May 2, 2025 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
3. ASCENT PHARMS INC
Ascent Pharmaceuticals Inc has filed for 4 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Ascent Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 2.5MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
4. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 4 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet | Prescription | ORAL | AB | Apr 10, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 15, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 15, 2025 |
| 10MG | tablet | Prescription | ORAL | AB | May 15, 2025 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
5. BIOCON PHARMA
Biocon Pharma Ltd has filed for 4 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Biocon Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 2.5MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
Manufacturing Plant Locations New
Biocon Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Biocon Pharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
6. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 3 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | May 15, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 15, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 15, 2025 |
Manufacturing Plant Locations New
Breckenridge's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Breckenridge as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
7. CHANGZHOU PHARM
Changzhou Pharmaceutical Factory has filed for 3 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Changzhou Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
Manufacturing Plant Locations New
Changzhou Pharm's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Changzhou Pharm as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| China |
| |||
8. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 4 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
9. INVAGEN PHARMS
Invagen Pharmaceuticals Inc has filed for 3 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Invagen Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
10. LUPIN LTD
Lupin Ltd has filed for 4 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet | Prescription | ORAL | AB | Mar 3, 2025 |
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
Manufacturing Plant Locations New
Lupin Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Lupin Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
11. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 4 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
12. SUNSHINE
Sunshine Lake Pharma Co Ltd has filed for 3 different strengths of generic version for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Sunshine.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 15MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
| 20MG | tablet | Prescription | ORAL | AB | May 14, 2025 |
Manufacturing Plant Locations New
Sunshine's manufacturing plants are situated in 6 countries - United States, Peru, India, Thailand, China, Mozambique. Given below are the details of these plant locations as well as the firm names of Sunshine as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||||||||||||||
| Peru |
| |||||||||||||||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||||||||||||||
| Thailand |
| |||||||||||||||||||||||||||||||||||||||||
| China |
| |||||||||||||||||||||||||||||||||||||||||
| Mozambique |
| |||||||||||||||||||||||||||||||||||||||||
13. TARO
Taro Pharmaceutical Industries Ltd has filed for 1 generic for Rivaroxaban. Given below are the details of the strengths of this generic introduced by Taro.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2.5MG | tablet | Prescription | ORAL | AB | Mar 3, 2025 |
Manufacturing Plant Locations New
Taro's manufacturing plants are situated in 3 countries - United States, Israel, Canada. Given below are the details of these plant locations as well as the firm names of Taro as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| Israel |
| |||||
| Canada |
| |||||